Status:
RECRUITING
Contrast-Enhanced Stereotactic Biopsy
Lead Sponsor:
Zuyderland Medisch Centrum
Collaborating Sponsors:
Hologic, Inc.
Conditions:
Breast Cancer
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Brief Summary
Contrast-enhanced mammography (CEM) is an emerging breast imaging modality that is based on dual-energy mammography and the injection of iodinated contrast agent. A typical CEM study consists of a low...
Detailed Description
Rationale: Contrast-enhanced mammography (CEM) is an emerging breast imaging modality that is based on dual-energy mammography and the injection of iodinated contrast agent. A typical CEM study consis...
Eligibility Criteria
Inclusion
- Women \>18 years of age;
- Recent detection of a ROL on CEM;
- Able to provide written informed consent.
Exclusion
- All men (male sex);
- Women (female sex) who are contra indicated for CESB (for example: impaired renal function, known hypersensitivity to iodinated contrast);
- Pregnant women.
Key Trial Info
Start Date :
October 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06062992
Start Date
October 13 2023
End Date
March 1 2026
Last Update
February 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland Medical Center
Sittard, Limburg, Netherlands, 6162BG